Neuroscience

Structure of the eye
#Cell therapy #FDA #Neurodegenerative disorders #Neurotech Pharmaceuticals #Ophthalmology

FDA approves first treatment for Macular Telangiectasia Type 2

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel).  MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients' quality of life.   Encelto utilises an encapsulated cell therapy… Read More

#News #Regulatory

Drugs targeting amyloid Plaque
#Alzheimer's #Drug safety #Eisai #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE)

Researchers call for extra safety monitoring of lecanemab

Researchers from the UK’s Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a new drug to treat Alzheimer’s disease (AD).  In a review article, published in the British Journal for Clinical Pharmacology, the researchers discuss the need for ongoing assessment of the safety… Read More

#News #Regulatory #Trending News

Neuroscience
#Neurodegenerative disorders #Neuroscience #Protein degradation #Start-ups #TRIMTECH Therapeutics

Start-up harnesses protein degradation for neurodegeneration

TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round.   The investment will support further development of the company’s pipeline of central nervous system (CNS) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.  … Read More

#Business & Investment #News #Start-up Zone

#Gender #Neuroscience #Precision medicine #Women’s Brain Foundation

The urgent need for sex and gender to be recognised in drug discovery

DDW Editor Reece Armstrong speaks to Dr Antonella Santuccione Chadha, CEO of the Women’s Brain Foundation (WBF) about the importance of sex and gender differences in drug discovery efforts. The topic of gender disparity is a prevailing issue in modern society and is something which has caused fierce debate across political… Read More

#Exclusive Content

Bladder
#EG 427 #Financing #Genetic medicines #Neurodegenerative disorders

EG 427 raises €27m to finance genetic medicines in neuro-urology

EG 427 has announced the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance – as part of the InnoBio investment strategy.    The proceeds from the financing will be used to fund the Phase Ib/IIa development of EG 427’s lead genetic medicine product,… Read More

#Business & Investment #News

Genetic engineering concept
#AskBio #FDA #Gene therapy #Neuroscience #Parkinson's

Further FDA support for Parkinson’s gene therapy

AskBio’s investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA).  The FDA decision follows a review of information and data provided by AskBio, including clinical evidence from the open label Phase… Read More

#News #Regulatory

#2025 predictions #Drug discovery #Neuroscience

Neuroscience: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, this was with a focus on technology, machine learning (ML) and artificial intelligence (AI). Here, looking at the neuroscience sector. At the Society for Neuroscience’s annual meeting, Neuroscience 2024, both the turnout and… Read More

#Business & Investment #Exclusive Content #Trends & Analysis

Map of Iceland
#Alzheimer's #Arctic Therapeutics #Dementia #Dermatology #Financing #Neuroscience

Scale-up explores anti-amyloid treatments for dementia

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a €26.5 million oversubscribed Series A financing from a syndicate of international investors.  The syndicate includes the EIC Fund, Iceland's largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The Lurie Family Foundation,… Read More

#Business & Investment #News

#Autism #Fast Track designation #FDA #Neuroscience #Spinogenix

FDA fast-tracks drug for autism cause Fragile X syndrome

The US Food and Drug Administration (FDA) has granted Fast Track designation to SPG601 for the treatment of people with Fragile X syndrome (FXS).  FXS, a known cause of autism, is the leading inherited form of intellectual disability that can produce a wide range of disabling symptoms, with many individuals… Read More

#News #Regulatory

Neurons in a brain with Alzheimer's disease
#Drug discovery #Mission Therapeutics #Mitophagy #Neurodegenerative disorders #Neuroscience

Can neurodegenerative diseases be tackled by enhancing mitophagy?

Mission Therapeutics, a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, has announced the publication of a review article titled ‘Targeting mitophagy in neurodegenerative diseases’ in the journal Nature Reviews Drug Discovery. The article outlines the progress scientists have made in identifying that mitochondrial dysfunction is… Read More

#News

Tau proteins
#Alzheimer's #Fast Track designation #FDA #Johnson & Johnson #Monoclonal antibodies #Neuroscience

Tau-directed mAb receives US FDA fast track designation

The US Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb).  The therapy from Johnson & Johnson is being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase IIb AuTonomy study.   It has shown potential in targeting disease-associated… Read More

#News #Regulatory

#Dementia #Genetics / genomics #Neurodegenerative disorders #Vesper Bio

POC study initiated for frontotemporal dementia treatment

Vesper Bio has initiated a Phase Ib/IIa Proof of Concept (POC) study of its lead candidate VES001 for frontotemporal dementia. The SORT-IN-2 study will evaluate VES001 in patients with mutations in their progranulin-coding gene (GRN), which are causal for FTD(GRN). FTD(GRN) is an early onset degenerative brain disease which is… Read More

#News

Human brain
#Acquisition #CNS #Excessive Daytime Sleepiness (EDS) #Narcolepsy #Neuraxpharm #Neuroscience #TG Therapeutics

Narcolepsy acquisitions to boost Neuraxpharm’s CNS reach

Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More

#Business & Investment #News

Neurons
#Cell therapy #GPCRs #Neurology #Neuroscience #Stanford University

New ‘PAGER’ technology could transform cell therapies

Researchers at Stanford University have built a new synthetic receptor with broad potential to programme cell activity, including immune response and neurological signalling.  Detailed in a paper published in Nature, the new synthetic receptor accommodates a broader range of inputs and… Read More

#Editor's Choice #News

Magic Mushrooms in laboratory. Psilocybin science and research.
#Alcohol Use Disorder #Mental health #Oncology #Psilocybin #Psychedelics #Psychiatry

Findings support positive mental health benefits of psychedelics

One or two doses of psilocybin may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests.   A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder.  In the… Read More

#News

#Astex Pharmaceuticals #Bioorthogonal chemistry #Click chemistry #Cognitive impairment #Covid-19 #Drug discovery #Life sciences #Long Covid #Molecular Biology #Neuroscience #Public health

Podcast: Innovative approaches to improving drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More

#News